Загрузка...
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5317297/ https://ncbi.nlm.nih.gov/pubmed/28243125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102756 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|